This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (18)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Are We Making Progress in Charting the Course?

Arch Neurol. 2005;62:351-352.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

While progressive motor and nonmotor decline is the expected natural course of Parkinson disease (PD), there is a remarkable paucity of data on what determines the rate of progression before and after the onset of symptoms. Using serial fluorodopa F 18 ([¹⁸F]fluorodopa) positron emission tomography (PET) in a prospective, longitudinal study of 31 patients with PD observed for more than 5 years, Hilker et al¹ found an annual decline in striatal [¹⁸F]fluorodopa ranging from 4.4% (caudate) to 6.3% (putamen). This is similar to other longitudinal studies of PD progression, using imaging ligands that either measure dopamine metabolism ([¹⁸F]fluorodopa PET) or target dopamine transporter (-carboxymethyoxy-3--[4-iodophenyl] tropane single-photon emission computed tomography), demonstrating an annualized rate of reduction in these striatal markers of about 4% to 13% in patients with PD compared with 0% to 2.5% change in healthy controls.^2-5 These imaging studies are consistent with pathological studies . . . [Full Text of this Article]

AUTHOR INFORMATION

Joseph Jankovic, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Nonlinear Progression of Parkinson Disease as Determined by Serial Positron Emission Tomographic Imaging of Striatal Fluorodopa F 18 Activity
Ruediger Hilker, Katherine Schweitzer, Silke Coburger, Mehran Ghaemi, Simon Weisenbach, Andreas H. Jacobs, Jobst Rudolf, Karl Herholz, and Wolf-Dieter Heiss
Arch Neurol. 2005;62(3):378-382.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Parkinson chimera
Lees
Neurology 2009;72:S2-S11.
ABSTRACT | FULL TEXT  

Etiopathogenesis of Parkinson Disease: A New Beginning?
Weidong Le et al.
Neuroscientist 2009;15:28-35.
ABSTRACT  

The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease
Pan et al.
Brain 2008;131:1969-1978.
ABSTRACT | FULL TEXT  

Hemiparkinsonism-hemiatrophy syndrome
Wijemanne and Jankovic
Neurology 2007;69:1585-1594.
ABSTRACT | FULL TEXT  

Genetic testing in Parkinson disease: promises and pitfalls.
Tan and Jankovic
Arch Neurol 2006;63:1232-1237.
FULL TEXT  

Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra.
Greffard et al.
Arch Neurol 2006;63:584-588.
ABSTRACT | FULL TEXT